Interpace Diagnostics Group Reports Fourth Quarter and Full Year 2016 Financial Results, Business Progress Against Plan and Recent Accomplishments

Reconciliation of Adjusted EBITDA (Unaudited)

($ in thousands)

Quarters Ended

Years Ended

December 31,

December 31,

2016

2015

2016

2015

Income (loss) from continuing operations

$        6,304

$    (19,259)

$   (8,410)

$ (31,070)

Depreciation and amortization- continuing operations

992

1,136

4,292

4,470

Stock-based compensation - continuing operations

23

2,138

131

3,128

Taxes

(108)

#

(449)

(162)

#

(13,136)

Interest expense

544

898

2,144

3,705

Asset impairment

-

-

3,363

-

Loss on extinguishment of debt

-

1,873

-

1,873

Goodwill impairment

-

15,666

-

15,666

Change in fair value of contingent consideration

(10,686)

(7,993)

(11,860)

(7,993)

Adjusted EBITDA

$       (2,931)

$       (5,990)

$ (10,502)

$ (23,357)